These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37165488)

  • 21. Reliable structural information for rational design of benzoxazole type potential cholesteryl ester transfer protein (CETP) inhibitors through multiple validated modeling techniques.
    Amin SA; Adhikari N; Gayen S; Jha T
    J Biomol Struct Dyn; 2019 Oct; 37(17):4528-4541. PubMed ID: 30488780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
    Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative studies of three cholesteryl ester transfer proteins and their interactions with known inhibitors.
    Wang Z; Niimi M; Ding Q; Liu Z; Wang L; Zhang J; Xu J; Fan J
    PLoS One; 2017; 12(8):e0180772. PubMed ID: 28767652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
    Armitage J; Holmes MV; Preiss D
    J Am Coll Cardiol; 2019 Feb; 73(4):477-487. PubMed ID: 30704580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors.
    Chang Y; Zhou S; Li E; Zhao W; Ji Y; Wen X; Sun H; Yuan H
    Eur J Med Chem; 2017 Jan; 126():143-153. PubMed ID: 27750148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
    Mabuchi H; Nohara A; Inazu A
    Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations.
    Äijänen T; Koivuniemi A; Javanainen M; Rissanen S; Rog T; Vattulainen I
    PLoS Comput Biol; 2014 Nov; 10(11):e1003987. PubMed ID: 25412509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk.
    Masson W; Lobo M; Siniawski D; Huerín M; Molinero G; Valéro R; Nogueira JP
    Diabetes Metab; 2018 Dec; 44(6):508-513. PubMed ID: 29523487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological evaluation of benzylamino-methanone based cholesteryl ester transfer protein inhibitors.
    Abu Sheikha G; Abu Khalaf R; Melhem A; Albadawi G
    Molecules; 2010 Aug; 15(8):5721-33. PubMed ID: 20724961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.
    Tchoua U; D'Souza W; Mukhamedova N; Blum D; Niesor E; Mizrahi J; Maugeais C; Sviridov D
    Cardiovasc Res; 2008 Mar; 77(4):732-9. PubMed ID: 18056760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and biophysical insight into cholesteryl ester-transfer protein.
    Hall J; Qiu X
    Biochem Soc Trans; 2011 Aug; 39(4):1000-5. PubMed ID: 21787337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
    Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C
    J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
    Quintão EC
    Eur J Clin Invest; 2016 Jun; 46(6):581-9. PubMed ID: 26992444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
    Nurmohamed NS; Ditmarsch M; Kastelein JJP
    Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.